GA
GILD icon

Goldstein Advisors’s Gilead Sciences GILD Stock Holding History

Goldstein Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$323K Buy
2,555
+2
+0.1% +$264 0.03% 179
2026
Q1 		$356K Buy
2,553
+173
+7% +$24.2K 0.04% 130
2025
Q4 		$292K Hold
2,380
– – 0.03% 150
2025
Q3 		$264K Sell
2,380
-45
-2% -$5.12K 0.03% 161
2025
Q2 		$269K Buy
2,425
+36
+2% +$3.83K 0.04% 146
2025
Q1 		$268K Buy
2,389
+34
+1% +$3.51K 0.04% 146
2024
Q4 		$218K Buy
+2,355
New +$212K 0.03% 172

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldstein Advisors's GILD Position: Q2 2026 in Review

Goldstein Advisors increased its Gilead Sciences (GILD) stake by 0.08% in Q2 2026, buying an estimated $264 and bringing the position to 2,555 shares worth $323K. The position accounts for 0.03% of the portfolio, ranked #179.

Goldstein Advisors first reported a position in GILD in Q4 2024 and has held it in 7 quarters since. The position peaked at $356K in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Goldstein Advisors held 2,555 shares of Gilead Sciences worth $323K as of Q2 2026.
  • Goldstein Advisors bought 2 Gilead Sciences shares in Q2 2026, an estimated $264.
  • Gilead Sciences made up 0.03% of Goldstein Advisors's portfolio in Q2 2026, its #179 holding.
  • Goldstein Advisors first reported a position in Gilead Sciences in Q4 2024 and has held it in 7 quarters since.
  • Goldstein Advisors's Gilead Sciences position peaked at $356K in Q1 2026.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Goldstein Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.